Ceramide participates in lysosome-mediated cell death induced by type II anti-CD20 monoclonal antibodies

References

• Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848–857.
   PubMed Web of Science ®Google Scholar
• van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies. Semin Hematol 2010;47:199–210.
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010;142:699–713.
   PubMed Web of Science ®Google Scholar
• Wu C, Li H, Zhao H, et al. Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery. Nanoscale Res Lett 2014;9:447.
   PubMed Web of Science ®Google Scholar
• Gupta P, Goldenberg DM, Rossi EA, et al. Dual-targeting immunotherapy of lymphoma:potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 2012;119:3767–3778.
   PubMed Web of Science ®Google Scholar
• Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117:4519–4529.
   PubMed Web of Science ®Google Scholar
• Zhao L, Tong Q, Qian W, et al. Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T-cell immunity by CD20-Flex BiFP. Blood 2013;122:4230–4236.
   PubMed Web of Science ®Google Scholar
• Trinh KR, Vasuthasawat A, Steward KK, et al. Anti-CD20-interferon-beta fusion protein therapy of murine B-cell lymphomas. J Immunother 2013;36:305–318.
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CH, James S, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008;112:4170–4177.
   PubMed Web of Science ®Google Scholar
• Zhao L, Xie F, Li H, et al. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab. MAbs 2014;6:739–747.
   Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823–3837.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008;20: 444–449.
   PubMed Web of Science ®Google Scholar
• Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies. PLoS One 2007;2:e326.
   Google Scholar
• Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005;304:88–99.
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280–3288.
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191–5201.
   PubMed Web of Science ®Google Scholar
• Li B, Zhao L, Guo H, et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009;114:5007–5015.
   PubMed Web of Science ®Google Scholar
• Buhmann R, Michael S, Juergen H, et al. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating phase I/II-trial. J Transl Med 2013;11:160.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Ma Y, Martin SM, et al. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother 2011;60:771–780.
   PubMed Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013;31:2912–2919.
   PubMed Web of Science ®Google Scholar
• Ogura M, Tobinai K, Hatake K, et al. Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2013;104:105–110.
   PubMed Web of Science ®Google Scholar
• Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119:2143–2159.
   PubMed Web of Science ®Google Scholar
• Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994;77:325–328.
   PubMed Web of Science ®Google Scholar
• Jarvis WD, Kolesnick RN, Fornari FA, et al. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc Natl Acad Sci USA 1994;91:73–77.
   PubMed Web of Science ®Google Scholar
• Gong L, Yang B, Xu M, et al. Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemother Pharmacol 2014;73:69–77.
   PubMed Web of Science ®Google Scholar
• Pelled D, Raveh T, Riebeling C, et al. Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons. J Biol Chem 2002;277:1957–1961.
   PubMed Web of Science ®Google Scholar
• Barthlen W, Schafer J, Girgert R, et al. Apoptosis of cultured neuroblastoma cells is induced by ceramide and not by ligation of the Fas/Apo-1/CD95 receptor. Chemotherapy 1999;45:258–267.
   PubMed Web of Science ®Google Scholar
• Taniwaki T, Yamada T, Asahara H, et al. Ceramide induces apoptosis to immature cerebellar granule cells in culture. Neurochem Res 1999;24:685–690.
   PubMed Web of Science ®Google Scholar
• Perry DK. The role of de novo ceramide synthesis in chemotherapy-induced apoptosis. Ann NY Acad Sci 2000;905:91–96.
   PubMed Web of Science ®Google Scholar
• Soeda S, Tsunoda T, Kurokawa Y, et al. Tumor necrosis factor-alpha-induced release of plasminogen activator inhibitor-1 from human umbilical vein endothelial cells:involvement of intracellular ceramide signaling event. Biochim Biophys Acta 1998;1448:37–45.
   PubMed Web of Science ®Google Scholar
• Perry DK. Serine palmitoyltransferase:role in apoptotic de novo ceramide synthesis and other stress responses. Biochim Biophys Acta 2002;1585:146–152.
   PubMed Web of Science ®Google Scholar
• Azzam R, Hariri F, El-Hachem N, et al. Regulation of de novo ceramide synthesis: the role of dihydroceramide desaturase and transcriptional factors NFATC and Hand2 in the hypoxic mouse heart. DNA Cell Biol 2013;32:310–319.
   PubMed Web of Science ®Google Scholar
• Merrill AJ, van Echten G, Wang E, et al. Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J Biol Chem 1993;268: 27299–27306.
   PubMed Web of Science ®Google Scholar
• Terszowski G, Klein C, Stern M. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity. J Immunol 2014;192:5618–5624.
   PubMed Web of Science ®Google Scholar
• Herting F, Friess T, Bader S, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma 2014;55:2151–2160.
   PubMed Web of Science ®Google Scholar
• Ohno T, Sakamoto T, Mizumoto C, et al. Leukemic and meningeal relapse of CD5 + intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy. Int J Hematol 2006;84:74–78.
   PubMed Web of Science ®Google Scholar
• Jilani I, O’Brien S, Manshuri T et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003;102:3514–3520.
   PubMed Web of Science ®Google Scholar
• Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 2002;8:2701–2713.
   PubMed Web of Science ®Google Scholar
• Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711–720.
   PubMed Web of Science ®Google Scholar